SCHEMBL4157370

SCHEMBL4157370

COC(=O)c1ccnc2[nH]c(-c3ccco3)nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.46
PKN1 Q16512 1/20 0.44
PKN2 Q16513 1/20 0.44
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
LMNA P02545 1/20 0.42
RAB9A P51151 4/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 3/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
MEN1 O00255 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
ESR2 Q92731 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CFTR P13569 2/20 0.40
ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153441 0.86 ALDH1A1 (0.42) LMNARAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL4145561 0.81 PKN1 (0.56) AXLPKN1PKN2LMNARAB9A
SCHEMBL8221064 0.81 ALDH1A1 (0.43) PKN1PKN2RAB9AALDH1A1KDM4E
SCHEMBL4144871 0.78 PKN1 (0.47) PKN1PKN2LMNARAB9AALDH1A1
SCHEMBL4160869 0.77 ALDH1A1 (0.45) LMNARAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL4157391 0.77 ERCC1 (0.54) PKN1PKN2RAB9AALDH1A1KDM4E
SCHEMBL4153447 0.76 PKN1 (0.51) PKN1PKN2LMNARAB9AALDH1A1
SCHEMBL4157420 0.76 PKN1 (0.51) PKN1PKN2LMNARAB9AALDH1A1
SCHEMBL17224923 0.76 PKN1 (0.51) PKN1PKN2LMNARAB9AALDH1A1
SCHEMBL4161193 0.75 PKN1 (0.45) PKN1PKN2GAAPSMD14MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 AXL 603/4885PKN1 527/4885PKN2 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.